Xiaoyu Wen

机构：Tianjin University of Technology, Tianjin University, Jilin University, Tiangong University, Changchun Observatory, First Hospital of Jilin University · ORCID：0000-0003-2109-1557

发表论文 49 篇 · 总被引 2028 次 · h-index 12

代表论文

• Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial (2023 · The Lancet · 被引 516)
• Donafenib Versus Sorafenib in First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma: A Randomized, Open-Label, Parallel-Controlled Phase II-III Trial (2021 · Journal of Clinical Oncology · 被引 417)
• Abstract CT003: IMbrave050: Phase 3 study of adjuvant atezolizumab + bevacizumab versus active surveillance in patients with hepatocellular carcinoma (HCC) at high risk of disease recurrence following resection or ablation (2023 · Cancer Research · 被引 44)
• Integrated Plasma Metabolomics and Gut Microbiota Analysis: The Intervention Effect of Jiawei Xiaoyao San on Liver Depression and Spleen Deficiency Liver Cancer Rats (2022 · Frontiers in Pharmacology · 被引 24)
• The prognostic value of antibodies to gp210 among patients with primary biliary cholangitis in Northeast China (2021 · Digestive and Liver Disease · 被引 12)
• The impact and role of hepatic hydrothorax in the prognosis of patients with decompensated cirrhosis: A retrospective propensity score-matched study (2022 · Frontiers in Medicine · 被引 6)